Difference in outcomes following allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia and myelodysplastic syndromes

被引：0

作者：

Yanada, Masamitsu ^{[1
]}

Mizuno, Shohei ^{[2
]}

Yamasaki, Satoshi ^{[3
]}

Harada, Kaito ^{[4
]}

Konuma, Takaaki ^{[5
]}

Tamaki, Hiroya ^{[6
]}

Shingai, Naoki ^{[7
]}

Uchida, Naoyuki ^{[8
]}

Ozawa, Yukiyasu ^{[9
]}

Tanaka, Masatsugu ^{[10
]}

Onizuka, Makoto ^{[4
]}

Sawa, Masashi ^{[11
]}

Nakamae, Hirohisa ^{[12
]}

Shiratori, Souichi ^{[13
]}

Matsuoka, Ken-ichi ^{[14
]}

Eto, Tetsuya ^{[15
]}

Kawakita, Toshiro ^{[16
]}

Maruyama, Yumiko ^{[17
]}

Ichinohe, Tatsuo ^{[18
]}

Kanda, Yoshinobu ^{[19
]}

Atsuta, Yoshiko ^{[20
,21
]}

Aoki, Jun ^{[22
]}

Yano, Shingo ^{[23
]}

机构：

[1] Aichi Canc Ctr, Nagoya, Japan

[2] Aichi Med Univ, Nagakute, Japan

[3] Kyushu Univ, Beppu Hosp, Beppu, Oita, Japan

[4] Tokai Univ, Sch Med, Isehara, Japan

[5] Univ Tokyo, Inst Med Sci, Tokyo, Japan

[6] Hyogo Coll Med, Nishinomiya, Japan

[7] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan

[8] Toranomon Gen Hosp, Tokyo, Japan

[9] Japanese Red Cross Nagoya First Hosp, Nagoya, Japan

[10] Kanagawa Canc Ctr, Yokohama, Japan

[11] Anjo Kosei Hosp, Anjo, Japan

[12] Osaka City Univ, Grad Sch Med, Osaka, Japan

[13] Hokkaido Univ, Fac Med, Sapporo, Japan

[14] Okayama Univ Hosp, Okayama, Japan

[15] Hamanoumachi Hosp, Fukuoka, Japan

[16] Natl Hosp Org Kumamoto Med Ctr, Kumamoto, Japan

[17] Univ Tsukuba, Fac Med, Tsukuba, Japan

[18] Hiroshima Univ, Res Inst Radiat Biol & Med, Hiroshima, Japan

[19] Jichi Med Univ, Shimotsuke, Japan

[20] Japanese Data Ctr Hematopoiet Cell Transplantat, Nagoya, Japan

[21] Nagoya Univ, Grad Sch Med, Nagoya, Japan

[22] Natl Canc Ctr, Tokyo, Japan

[23] Jikei Univ, Sch Med, Tokyo, Japan

来源：

LEUKEMIA & LYMPHOMA | 2021年 / 62卷 / 14期

关键词：

Acute myeloid leukemia; myelodysplastic syndrome; allogeneic hematopoietic cell transplantation; INTERNATIONAL WORKING GROUP; WORLD-HEALTH-ORGANIZATION; VERSUS-HOST-DISEASE; RESPONSE CRITERIA; CONDITIONING INTENSITY; CLASSIFICATION; NEOPLASMS; RECOMMENDATIONS; DIAGNOSIS; REVISION;

D O I：

10.1080/10428194.2021.1961242

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

To evaluate whether outcomes following allogeneic hematopoietic cell transplantation differ according to disease type, a three-way comparison for patients with de novo acute myeloid leukemia (AML) (n = 3318), AML evolving from myelodysplastic syndromes (MDS) (n = 208), and MDS with excess blasts (MDS-EB) (n = 994) was performed. The 5-year probabilities of overall survival (OS) for de novo AML, AML evolving from MDS, and MDS-EB were 60%, 42%, and 41% (p < 0.001), respectively. Multivariate analysis revealed that, compared to de novo AML, AML evolving from MDS was associated with a higher risk of NRM (p = 0.030) and MDS-EB with a higher risk of relapse (p < 0.001), both leading to lower OS (p = 0.010 and p < 0.001, respectively). These findings demonstrate inter-disease differences in post-transplant outcomes and highlight the needs to reduce NRM for AML evolving from MDS and to reduce relapse for MDS-EB.

引用

页码：3411 / 3419

页数：9

共 35 条

[1] The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Arber, Daniel A.
Orazi, Attilio
Hasserjian, Robert
Thiele, Jurgen
Borowitz, Michael J.
Le Beau, Michelle M.
Bloomfield, Clara D.
Cazzola, Mario
Vardiman, James W.
[J]. BLOOD, 2016, 127 (20) : 2391 - 2405
[2] Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data)
Atsuta, Yoshiko
[J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 103 (01) : 3 - 10
[3] Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial
Bornhaeuser, Martin
Kienast, Joachim
Trenschel, Rudolf
Burchert, Andreas
Hegenbart, Ute
Stadler, Michael
Baurmann, Herrad
Schaefer-Eckart, Kerstin
Holler, Ernst
Kroeger, Nicolaus
Schmid, Christoph
Einsele, Herrmann
Kiehl, Michael G.
Hiddemann, Wolfgang
Schwerdtfeger, Rainer
Buchholz, Stefanie
Dreger, Peter
Neubauer, Andreas
Berdel, Wolfgang E.
Ehninger, Gerhard
Beelen, Dietrich W.
Schetelig, Johannes
Stelljes, Matthias
[J]. LANCET ONCOLOGY, 2012, 13 (10) : 1035 - 1044
[4] Myelodysplastic Syndromes
Cazzola, Mario
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (14) : 1358 - 1374
[5] Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
Cheson, BD
Bennett, JM
Kopecky, KJ
Büchner, T
Willman, CL
Estey, EH
Schiffer, CA
Döhner, H
Tallman, MS
Lister, TA
LoCocco, F
Willemze, R
Biondi, A
Hiddemann, W
Larson, RA
Löwenberg, B
Sanz, MA
Head, DR
Ohno, R
Bloomfield, CD
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) : 4642 - 4649
[6] Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Cheson, Bruce D.
Greenberg, Peter L.
Bennett, John M.
Lowenberg, Bob
Wijermans, Pierre W.
Nimer, Stephen D.
Pinto, Antonio
Beran, Miloslav
de Witte, Theo M.
Stone, Richard M.
Mittelman, Moshe
Sanz, Guillermo F.
Gore, Steven D.
Schiffer, Charles A.
Kantarjian, Hagop
[J]. BLOOD, 2006, 108 (02) : 419 - 425
[7] Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel
de Witte, Theo
Bowen, David
Robin, Marie
Malcovati, Luca
Niederwieser, Dietger
Yakoub-Agha, Ibrahim
Mufti, Ghulam J.
Fenaux, Pierre
Sanz, Guillermo
Martino, Rodrigo
Alessandrino, Emilio Paolo
Onida, Francesco
Symeonidis, Argiris
Passweg, Jakob
Kobbe, Guido
Ganser, Arnold
Platzbecker, Uwe
Finke, Jurgen
van Gelder, Michel
van de Loosdrecht, Arjan A.
Ljungman, Per
Stauder, Reinhard
Volin, Liisa
Deeg, H. Joachim
Cutler, Corey
Saber, Wael
Champlin, Richard
Giralt, Sergio
Anasetti, Claudio
Kroeger, Nicolaus
[J]. BLOOD, 2017, 129 (13) : 1753 - 1762
[8] Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation
Della Porta, Matteo G.
Galli, Anna
Bacigalupo, Andrea
Zibellini, Silvia
Bernardi, Massimo
Rizzo, Ettore
Allione, Bernardino
van Lint, Maria Teresa
Pioltelli, Pietro
Marenco, Paola
Bosi, Alberto
Voso, Maria Teresa
Sica, Simona
Cuzzola, Mariella
Angelucci, Emanuele
Rossi, Marianna
Ubezio, Marta
Malovini, Alberto
Limongelli, Ivan
Ferretti, Virginia V.
Spinelli, Orietta
Tresoldi, Cristina
Pozzi, Sarah
Luchetti, Silvia
Pezzetti, Laura
Catricala, Silvia
Milanesi, Chiara
Riva, Alberto
Bruno, Benedetto
Ciceri, Fabio
Bonifazi, Francesca
Bellazzi, Riccardo
Papaemmanuil, Elli
Santoro, Armando
Alessandrino, Emilio P.
Rambaldi, Alessandro
Cazzola, Mario
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (30) : 3627 - +
[9] Hematopoietic Stem-Cell Transplantation for Acute Leukemia in Relapse or Primary Induction Failure
Duval, Michel
Klein, John P.
He, Wensheng
Cahn, Jean-Yves
Cairo, Mitchell
Camitta, Bruce M.
Kamble, Rammurti
Copelan, Edward
de Lima, Marcos
Gupta, Vikas
Keating, Armand
Lazarus, Hillard M.
Litzow, Mark R.
Marks, David I.
Maziarz, Richard T.
Rizzieri, David A.
Schiller, Gary
Schultz, Kirk R.
Tallman, Martin S.
Weisdorf, Daniel
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (23) : 3730 - 3738
[10] National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report
Filipovich, AH
Weisdorf, D
Pavletic, S
Socie, G
Wingard, JR
Lee, SJ
Martin, P
Chien, J
Przepiorka, D
Couriel, D
Cowen, EW
Dinndorf, P
Farrell, A
Hartzman, R
Henslee-Downey, J
Jacobsohn, D
McDonald, G
Mittleman, B
Rizzo, JD
Robinson, M
Schubert, M
Schultz, K
Shulman, H
Turner, M
Vogelsang, G
Flowers, MED
[J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (12) : 945 - 956

← 1 2 3 4 →